Szérum keratán szulfát vizsgálatok és jelentöségük a porcdegradáció megítélésében degeneratív és gyulladásos ízületi betegségekben.

Translated title of the contribution: Serum keratan sulfate studies and their significance in the evaluation of cartilage degradation in degenerative and inflammatory joint diseases

A. M. Sárközi, G. Hámori, C. Fülöp, E. Búzás, M. Brózik, K. Merétey, T. T. Glant

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fragments of high density cartilage proteoglycan (aggrecan) are released during either the normal or pathological turnover of cartilage proteoglycans, which fragments diffuse into the synovial fluids and then appear in the serum. The keratan sulphate (KS; a glycosaminoglycan side chain of aggrecan) is resistant to enzymatic degradation, it has a relatively low clearance and has a "standard" serum level indicating the actual level of cartilage (proteoglycan) breakdown. Using anti-KS monoclonal antibody in ELISA (enzyme-linked immunosorbent assay), we measured serum KS levels in patients with different joint diseases. The highest KS content (595 ng/ml) was measured in the sera of patients with articular chondrocalcinosis (calcium pyrophosphate crystal deposition disease/pseudogout). Slightly lower KS levels were determined in osteoarthrosis (OA; 578 ng/ml) and much less in rheumatoid arthritis (RA; 421 ng/ml). All these patient groups (either with degenerative or inflammatory joint diseases) expressed slightly higher KS levels compared to control blood donors (295 ng/ml). However, there were remarkable variations between these diseased groups, i. e., KS levels in patients with RA were significantly lower than in patients with OA (p <0.001) and this difference was more pronounced in rheumatoid patients with I-II Steinbrocker stage (370 ng/ml) or in those treated with non-steroid anti-inflammatory drugs (NSAIDs) (382 ng/ml). Keratan sulphate levels in RA patients chronically treated with corticosteroid (460 ng/ml) or auro-thiomalat (473 ng/ml) indicate that these drugs may influence the cartilage metabolism more effectively than the NSAIDs.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageHungarian
Pages (from-to)461-467
Number of pages7
JournalOrvosi Hetilap
Volume134
Issue number9
Publication statusPublished - Feb 28 1993

Fingerprint

Keratan Sulfate
Osteoarthritis
Cartilage
Chondrocalcinosis
Serum
Proteoglycans
Aggrecans
Joint Diseases
Anti-Inflammatory Agents
Pharmaceutical Preparations
Synovial Fluid
Glycosaminoglycans
Blood Donors
Rheumatoid Arthritis
Adrenal Cortex Hormones
Joints
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szérum keratán szulfát vizsgálatok és jelentöségük a porcdegradáció megítélésében degeneratív és gyulladásos ízületi betegségekben. / Sárközi, A. M.; Hámori, G.; Fülöp, C.; Búzás, E.; Brózik, M.; Merétey, K.; Glant, T. T.

In: Orvosi Hetilap, Vol. 134, No. 9, 28.02.1993, p. 461-467.

Research output: Contribution to journalArticle

Sárközi, A. M. ; Hámori, G. ; Fülöp, C. ; Búzás, E. ; Brózik, M. ; Merétey, K. ; Glant, T. T. / Szérum keratán szulfát vizsgálatok és jelentöségük a porcdegradáció megítélésében degeneratív és gyulladásos ízületi betegségekben. In: Orvosi Hetilap. 1993 ; Vol. 134, No. 9. pp. 461-467.
@article{a2f6214a694143218d030c36b7153d7e,
title = "Sz{\'e}rum kerat{\'a}n szulf{\'a}t vizsg{\'a}latok {\'e}s jelent{\"o}s{\'e}g{\"u}k a porcdegrad{\'a}ci{\'o} meg{\'i}t{\'e}l{\'e}s{\'e}ben degenerat{\'i}v {\'e}s gyullad{\'a}sos {\'i}z{\"u}leti betegs{\'e}gekben.",
abstract = "Fragments of high density cartilage proteoglycan (aggrecan) are released during either the normal or pathological turnover of cartilage proteoglycans, which fragments diffuse into the synovial fluids and then appear in the serum. The keratan sulphate (KS; a glycosaminoglycan side chain of aggrecan) is resistant to enzymatic degradation, it has a relatively low clearance and has a {"}standard{"} serum level indicating the actual level of cartilage (proteoglycan) breakdown. Using anti-KS monoclonal antibody in ELISA (enzyme-linked immunosorbent assay), we measured serum KS levels in patients with different joint diseases. The highest KS content (595 ng/ml) was measured in the sera of patients with articular chondrocalcinosis (calcium pyrophosphate crystal deposition disease/pseudogout). Slightly lower KS levels were determined in osteoarthrosis (OA; 578 ng/ml) and much less in rheumatoid arthritis (RA; 421 ng/ml). All these patient groups (either with degenerative or inflammatory joint diseases) expressed slightly higher KS levels compared to control blood donors (295 ng/ml). However, there were remarkable variations between these diseased groups, i. e., KS levels in patients with RA were significantly lower than in patients with OA (p <0.001) and this difference was more pronounced in rheumatoid patients with I-II Steinbrocker stage (370 ng/ml) or in those treated with non-steroid anti-inflammatory drugs (NSAIDs) (382 ng/ml). Keratan sulphate levels in RA patients chronically treated with corticosteroid (460 ng/ml) or auro-thiomalat (473 ng/ml) indicate that these drugs may influence the cartilage metabolism more effectively than the NSAIDs.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "S{\'a}rk{\"o}zi, {A. M.} and G. H{\'a}mori and C. F{\"u}l{\"o}p and E. B{\'u}z{\'a}s and M. Br{\'o}zik and K. Mer{\'e}tey and Glant, {T. T.}",
year = "1993",
month = "2",
day = "28",
language = "Hungarian",
volume = "134",
pages = "461--467",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "9",

}

TY - JOUR

T1 - Szérum keratán szulfát vizsgálatok és jelentöségük a porcdegradáció megítélésében degeneratív és gyulladásos ízületi betegségekben.

AU - Sárközi, A. M.

AU - Hámori, G.

AU - Fülöp, C.

AU - Búzás, E.

AU - Brózik, M.

AU - Merétey, K.

AU - Glant, T. T.

PY - 1993/2/28

Y1 - 1993/2/28

N2 - Fragments of high density cartilage proteoglycan (aggrecan) are released during either the normal or pathological turnover of cartilage proteoglycans, which fragments diffuse into the synovial fluids and then appear in the serum. The keratan sulphate (KS; a glycosaminoglycan side chain of aggrecan) is resistant to enzymatic degradation, it has a relatively low clearance and has a "standard" serum level indicating the actual level of cartilage (proteoglycan) breakdown. Using anti-KS monoclonal antibody in ELISA (enzyme-linked immunosorbent assay), we measured serum KS levels in patients with different joint diseases. The highest KS content (595 ng/ml) was measured in the sera of patients with articular chondrocalcinosis (calcium pyrophosphate crystal deposition disease/pseudogout). Slightly lower KS levels were determined in osteoarthrosis (OA; 578 ng/ml) and much less in rheumatoid arthritis (RA; 421 ng/ml). All these patient groups (either with degenerative or inflammatory joint diseases) expressed slightly higher KS levels compared to control blood donors (295 ng/ml). However, there were remarkable variations between these diseased groups, i. e., KS levels in patients with RA were significantly lower than in patients with OA (p <0.001) and this difference was more pronounced in rheumatoid patients with I-II Steinbrocker stage (370 ng/ml) or in those treated with non-steroid anti-inflammatory drugs (NSAIDs) (382 ng/ml). Keratan sulphate levels in RA patients chronically treated with corticosteroid (460 ng/ml) or auro-thiomalat (473 ng/ml) indicate that these drugs may influence the cartilage metabolism more effectively than the NSAIDs.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - Fragments of high density cartilage proteoglycan (aggrecan) are released during either the normal or pathological turnover of cartilage proteoglycans, which fragments diffuse into the synovial fluids and then appear in the serum. The keratan sulphate (KS; a glycosaminoglycan side chain of aggrecan) is resistant to enzymatic degradation, it has a relatively low clearance and has a "standard" serum level indicating the actual level of cartilage (proteoglycan) breakdown. Using anti-KS monoclonal antibody in ELISA (enzyme-linked immunosorbent assay), we measured serum KS levels in patients with different joint diseases. The highest KS content (595 ng/ml) was measured in the sera of patients with articular chondrocalcinosis (calcium pyrophosphate crystal deposition disease/pseudogout). Slightly lower KS levels were determined in osteoarthrosis (OA; 578 ng/ml) and much less in rheumatoid arthritis (RA; 421 ng/ml). All these patient groups (either with degenerative or inflammatory joint diseases) expressed slightly higher KS levels compared to control blood donors (295 ng/ml). However, there were remarkable variations between these diseased groups, i. e., KS levels in patients with RA were significantly lower than in patients with OA (p <0.001) and this difference was more pronounced in rheumatoid patients with I-II Steinbrocker stage (370 ng/ml) or in those treated with non-steroid anti-inflammatory drugs (NSAIDs) (382 ng/ml). Keratan sulphate levels in RA patients chronically treated with corticosteroid (460 ng/ml) or auro-thiomalat (473 ng/ml) indicate that these drugs may influence the cartilage metabolism more effectively than the NSAIDs.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0027925196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027925196&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 461

EP - 467

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 9

ER -